Home
IMPACT PH Lecture Series
Education
PAH.tv Network
Slidesets and Resources
You are here :
PAH.tv Network
Login
|
Register
Please select a video from the list below.
Hemodynamics Markers of PH and Outcomes in Heart Failure With HFpEF
Heart failure with preserved ejection fraction (HFpEF) is highly prevalent, yet there are no specific therapies, possibly due to phenotypic heterogeneity. In this episode of PH Weekly: Outcomes 365, Dr. Jean Elwing presents the results from a recent paper by Vanderpool et al (2018), which examined a large cohort of patients where PH-HFpEF was common and determined associations between key hemodynamic parameters and essential aspects of morbidity and mortality.
Recent Video
|
Most Viewed
Specialties :
<All Specialties>
Allied Health
Clinical Insights
Clinical Trials
Lecturer Bios
News
PAH
Search :
Hemodynamics Markers of PH and Outcomes in Heart Failure With HFpEF
Views - 68
Clinical Worsening in Higher Risk Patients
Views - 107
Approach to Treatment in Inoperable CTEPH
Views - 158
Transitioning Patients Between PH Therapies
Views - 287
Plasma BNP Predicts 5-Year Overall Survival in PAH
Views - 309
Are Direct Oral Anticoagulants Appropriate for PAH?
Views - 376
Options When Prostacyclin Side Effects are Unmanageable
Views - 396
SIOVAC: Sildenafil for PH after Mitral Valve Surgery
Views - 2364
Macitentan in PH Due to LV Dysfunction: MELODY-1
Views - 486
Is Up-Front Triple Combination Therapy in PAH "A Thing"?
Views - 435
New Therapies for CTEPH
Views - 347
New Therapies for Group 1 PAH
Views - 423
How to Screen for PAH in Scleroderma-Spectrum Disorders
Views - 451
PAH-Related Morbidity Is Prognostic for Mortality
Views - 753
Pulmonary Hypertension Association Update
Views - 192
Getting Aggressive in PAH: Setting Goals and Escalating Care
Views - 545
Strategies for Transitioning Therapy in PAH
Views - 56
Palliative Care in PAH: Best Practice or Too Little, Too Late
Views - 74
Newer Medications and How To Use Them
Views - 77
Clinical Research Year in Review
Views - 58
Advances in Imaging for Lung Vasculature
Views - 64
Bleeding and Thrombosis After PTE
Views - 40
Serum CXC-Chemokine Ligand 10 is Associated with Severity of Chronic Thromboembolic Pulmonary Hypertension
Views - 28
NEDD9 is Upregulated By Hypoxia in Human Pulmonary Artery Endothelial Cells Selectively and Modulates Platelet-Endothelial Adhesion
Views - 36
Management of Severe Right Heart Failure in PTE Patients
Views - 36
The Imposters: What (almost) Everyone Thinks is CTEPH
Views - 32
Absence of the Factor V Leiden Mutation and Genetic Risk For CTEPH
Views - 54
Pulmonary Embolism, CTED and CTEPH: Connecting the Dots
Views - 48
Evaluation of CTEPH: VQ Scans and Planar Angiography
Views - 41
Patients with CTEPH Should Be Started on PAH Therapy Prior to PTE
Views - 60
An Overview of PH Directed Medical Therapy in CTEPH
Views - 48
CTED and the Value of Exercise Testing
Views - 30
Future Directions in CTEPH
Views - 49
Balloon Pulmonary Angioplasty for CTEPH: Patient Selection
Views - 56
CTEPH Patients Should NOT Be Started on PH Medical Therapy Before PTE
Views - 21
Mechanism of Lumen Enlargement and Pulmonary Injury In Balloon Pulmonary Angioplasty for Chronic Thromboembolic Pulmonary Hypertension
Views - 18
Distal Pulmonary Thromboendarterecomy: Is It Worth It?
Views - 17
Medical Decision in BPA
Views - 35
The Pursuit of Minimally Invasive Pulmonary Thromboendarterectomy
Views - 13
The Dilemma of CTEPH
Views - 92
Challenges of PAH in Heart Failure With Preserved Ejection Fraction
Views - 1936
Weighing Strategic Treatment Options in the Current Era of PAH Medicine
Views - 1308
Expanding the Therapeutic Range of Current PAH Medications: What Next?
Views - 118
Selexipag for the Treatment of Connective Tissue Disease-Associated PAH
Views - 302
RESPITE Study Results
Views - 1220
Assessing Risk in PAH Patients
Views - 955
When to Add or Switch Therapy
Views - 388
RESPITE: Evidence to Support a Switch Approach?
Views - 545
Switching from PDE-5 to sGC Stimulator
Views - 257
What is Tolerance to Therapy on PDE-5 or PGI-2?
Views - 199
What are the Choices When Escalating Therapy?
Views - 907
Parameters for Treatment Success
Views - 797
When Should Patients be Evaluated for Efficacy?
Views - 311
General Goals of Therapy for Patient on Monotherapy
Views - 1698
Early Combination Therapy: Applying Aggressive Goals
Views - 163
Preventing Hospitalization in PAH Through Aggressive Early Therapy
Views - 197
Future Directions in PAH Therapy and Clinical Research
Views - 643
Quality of Life Issues in the Treatment of PAH
Views - 1215
What Are the Risks to Combination Therapy?
Views - 83
Neurohormone in the Pathobiology of PH: Beta-blockers
Views - 65
Palliative Care in Pulmonary Arterial Hypertension
Views - 162
Oral Prostanoids for the Mgmt of PH: The Holy Grail or Beraprost Revisited?
Views - 379
Neurohormone in the pathobiology of PH: RAAS
Views - 46
Case Presentation: Palliative Care in PAH
Views - 23
Mitral Valve Disease and the Development of Pulmonary Arteriopathy
Views - 150
Vascular and Endothelial Biomarkers in PAH
Views - 54
Case of Atrial Septal Defect Associated with PH
Views - 1664
WHO Group II PH Due to Heart Failure w/Preserved Ejection Fraction
Views - 829
Case of a 58 Year Old with Scleroderma
Views - 494
Understanding the Diagnosis and Treatment of PAH
Views - 405
20 Years of Prostanoids: Spanning the Continuum of Care in PAH
Views - 724
Group 1 and Beyond: Case Studies in PH
Views - 230
Insights from Fetal Imaging
Views - 115
Pathophysiology of PH in the ICU
Views - 113
ICU Management of PH
Views - 158
Privacy
|
Terms Of Use
|
Contact Us
|
Copyright 2019 by PAH.tv
|
About PAH.tv